Movatterモバイル変換

[0]ホーム
URL:

MX373328B - Treatment of immune-related and inflammatory diseases - Google Patents

Treatment of immune-related and inflammatory diseases

Info

Publication number
MX373328B
MX373328BMX2015001686AMX2015001686AMX373328BMX 373328 BMX373328 BMX 373328BMX 2015001686 AMX2015001686 AMX 2015001686AMX 2015001686 AMX2015001686 AMX 2015001686AMX 373328 BMX373328 BMX 373328B
Authority
MX
Mexico
Prior art keywords
immune
inflammatory diseases
treatment
methods
cells
Prior art date
Application number
MX2015001686A
Other languages
Spanish (es)
Other versions
MX2015001686A (en
Inventor
Anita Gandhi
Peter H Schafer
Rajesh Chopra
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene CorpfiledCriticalCelgene Corp
Publication of MX2015001686ApublicationCriticalpatent/MX2015001686A/en
Publication of MX373328BpublicationCriticalpatent/MX373328B/en

Links

Classifications

Landscapes

Abstract

Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.
MX2015001686A2012-08-092013-08-08Treatment of immune-related and inflammatory diseasesMX373328B (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US201261681491P2012-08-092012-08-09
US201261722718P2012-11-052012-11-05
PCT/US2013/054051WO2014025958A2 (en)2012-08-092013-08-08Treatment of immune-related and inflammatory diseases

Publications (2)

Publication NumberPublication Date
MX2015001686A MX2015001686A (en)2015-04-10
MX373328Btrue MX373328B (en)2020-05-04

Family

ID=49029213

Family Applications (1)

Application NumberTitlePriority DateFiling Date
MX2015001686AMX373328B (en)2012-08-092013-08-08Treatment of immune-related and inflammatory diseases

Country Status (30)

CountryLink
US (2)US10919883B2 (en)
EP (2)EP3741372A1 (en)
JP (2)JP6250671B2 (en)
KR (3)KR102118559B1 (en)
CN (4)CN104703605A (en)
AU (1)AU2013299625B2 (en)
BR (1)BR112015002272A2 (en)
CA (2)CA3092279C (en)
CY (1)CY1123106T1 (en)
DK (1)DK2882441T3 (en)
EA (1)EA029085B1 (en)
ES (1)ES2800026T3 (en)
HR (1)HRP20200836T1 (en)
HU (1)HUE049569T2 (en)
IL (1)IL237070B (en)
LT (1)LT2882441T (en)
MX (1)MX373328B (en)
NI (1)NI201500013A (en)
NZ (2)NZ727295A (en)
PH (1)PH12015500276A1 (en)
PL (1)PL2882441T3 (en)
PT (1)PT2882441T (en)
RS (1)RS60416B1 (en)
SG (1)SG11201500983RA (en)
SI (1)SI2882441T1 (en)
SM (1)SMT202000333T1 (en)
TW (1)TWI641371B (en)
UA (1)UA116992C2 (en)
WO (1)WO2014025958A2 (en)
ZA (1)ZA201500466B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
UA114856C2 (en)2010-02-112017-08-10Селджин Корпорейшн METHODS OF TREATMENT WITH THE APPLICATION OF ARYLMETOXISOINDOLINE DERIVATIVES
AU2012236655B2 (en)2011-03-282016-09-22Deuterx, Llc,2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US20150038511A1 (en)2012-08-092015-02-05Celgene CorporationTreatment of immune-related and inflammatory diseases
EP2943201B2 (en)2013-01-142020-07-29Deuterx, LLC3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en)2013-01-222014-07-31Celgene CorporationProcesses for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US9290475B2 (en)2013-03-142016-03-22Deuterx, Llc3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
WO2015179279A1 (en)*2014-05-192015-11-26Celgene CorporationTreatment of immune-related and inflammatory diseases
JP2017522270A (en)2014-05-192017-08-10セルジーン コーポレイション 3- (4-((4- (morpholinomethyl-benzyl) oxy) -1-oxoisoindoline-2-yl) piperidine-2,6-dione for the treatment of systemic lupus erythematosus
US9809603B1 (en)2015-08-182017-11-07Deuterx, LlcDeuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
RU2748278C2 (en)2016-07-152021-05-21Акселерон Фарма Инк.Compositions and methods of pulmonary hypertension treatment
WO2019226770A1 (en)*2018-05-232019-11-28Celgene CorporationTreating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
AU2019351811B2 (en)2018-10-012025-01-02Celgene CorporationCombination therapy for the treatment of cancer
CA3127928A1 (en)*2019-01-282020-08-06SanofiMethods of treating multiple myeloma
US11609233B2 (en)2019-03-282023-03-21Alentic Microscience Inc.Indicator-based analysis of a sample
US10684278B1 (en)2019-03-282020-06-16Alentic Microscience Inc.Bead-based analysis of a sample
US11255850B2 (en)2019-03-282022-02-22Alentic Microscience Inc.Bead-based analysis of a sample
US11719700B2 (en)2019-03-282023-08-08Alentic Microscience Inc.Upconversion for microscopy
WO2021108303A1 (en)*2019-11-252021-06-03PHPrecisionMed, LLCPharmaceutical compositions for the treatment of pulmonary hypertension
WO2023097111A2 (en)*2021-11-292023-06-01Riptide Bioscience, Inc.Methods and compositions for treating calcinosis associated conditions
WO2024064646A1 (en)2022-09-202024-03-28Celgene CorporationSalts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3536809A (en)1969-02-171970-10-27Alza CorpMedication method
US3598123A (en)1969-04-011971-08-10Alza CorpBandage for administering drugs
US3845770A (en)1972-06-051974-11-05Alza CorpOsmatic dispensing device for releasing beneficial agent
US3916899A (en)1973-04-251975-11-04Alza CorpOsmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)1976-02-021977-02-22Alza CorporationOsmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (en)1984-10-041989-07-21몬산토 캄파니Composition of prolonged release of biologically active somatotropin
IE58110B1 (en)1984-10-301993-07-14Elan Corp PlcControlled release powder and process for its preparation
US5073543A (en)1988-07-211991-12-17G. D. Searle & Co.Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en)1989-03-221991-07-25Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
PH30995A (en)1989-07-071997-12-23Novartis IncSustained release formulations of water soluble peptides.
US5120548A (en)1989-11-071992-06-09Merck & Co., Inc.Swelling modulated polymeric drug delivery device
KR0166088B1 (en)1990-01-231999-01-15. Cyclodextrin derivatives with increased water solubility and uses thereof
US5733566A (en)1990-05-151998-03-31Alkermes Controlled Therapeutics Inc. IiControlled release of antiparasitic agents in animals
US5580578A (en)1992-01-271996-12-03Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en)1992-12-071998-06-11Takeda Pharm Ind Co LtdA pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en)1993-01-251997-01-07Pharmetrix CorporationLiquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en)1993-06-242000-07-11Takeda Chemical Industries, Ltd.Sustained-release preparation
IT1270594B (en)1994-07-071997-05-07Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
DE69632684T2 (en)1995-06-272005-06-09Takeda Pharmaceutical Co. Ltd. PROCESS FOR PREPARING PREPARED DELETION PREPARATIONS
TW448055B (en)1995-09-042001-08-01Takeda Chemical Industries LtdMethod of production of sustained-release preparation
JP2909418B2 (en)1995-09-181999-06-23株式会社資生堂 Delayed release microsphere of drug
US5980945A (en)1996-01-161999-11-09Societe De Conseils De Recherches Et D'applications Scientifique S.A.Sustained release drug formulations
US6264970B1 (en)1996-06-262001-07-24Takeda Chemical Industries, Ltd.Sustained-release preparation
US5635517B1 (en)1996-07-241999-06-29Celgene CorpMethod of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6419961B1 (en)1996-08-292002-07-16Takeda Chemical Industries, Ltd.Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en)1996-10-091998-04-09Sumitomo Pharmaceuticals Co., Ltd.Sustained release formulation
DE69730093T2 (en)1996-10-312006-07-20Takeda Pharmaceutical Co. Ltd. Preparation with delayed release
US6197350B1 (en)1996-12-202001-03-06Takeda Chemical Industries, Ltd.Method of producing a sustained-release preparation
US5891474A (en)1997-01-291999-04-06Poli Industria Chimica, S.P.A.Time-specific controlled release dosage formulations and method of preparing same
KR20070040423A (en)1998-03-162007-04-16셀진 코포레이션 2- (2,6-dioxopiperidin-3-yl) isoindolin derivatives for inflammatory cytokine inhibitors, preparations thereof and uses thereof
US6613358B2 (en)1998-03-182003-09-02Theodore W. RandolphSustained-release composition including amorphous polymer
KR19990085365A (en)1998-05-161999-12-06허영섭 Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof
US6248363B1 (en)1999-11-232001-06-19Lipocine, Inc.Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6984522B2 (en)*2000-08-032006-01-10Regents Of The University Of MichiganIsolation and use of solid tumor stem cells
EP1356075A4 (en)2000-10-162005-04-13Compound Therapeutics IncProtein scaffolds for antibody mimics and other binding proteins
US7754208B2 (en)2001-01-172010-07-13Trubion Pharmaceuticals, Inc.Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)2001-01-172003-07-17Genecraft, Inc.Binding domain-immunoglobulin fusion proteins
JP4369662B2 (en)2001-04-262009-11-25アビディア インコーポレイテッド Combinatorial library of monomer domains
GB0120441D0 (en)2001-08-222001-10-17Novartis ForschungsstiftungModel of autoimmune disease and methods for identifying anti autoimmune disease disorders
US7173032B2 (en)*2001-09-212007-02-06Reddy Us Therapeutics, Inc.Methods and compositions of novel triazine compounds
AU2005307789A1 (en)2004-11-162006-05-26Avidia Research InstituteProtein scaffolds and uses thereof
AU2007249805B2 (en)2006-05-122013-01-10University Of MiamiBiomarkers for detection and diagnosis of head and neck squamous cell carcinoma
US20080045485A1 (en)2006-08-172008-02-21Peter MuirMethods of diagnosing synovial disease in a mammal by detecting bacterial DNA in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture
NZ577111A (en)2006-12-152012-05-25Abbott LabNovel oxadiazole compounds
EP3101017B1 (en)2007-03-202019-06-12Celgene Corporation4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
US20100075333A1 (en)*2007-03-302010-03-25Alain MoreauMethod of determining the risk of scoliosis
JP5442185B2 (en)*2007-04-242014-03-12日本メナード化粧品株式会社 Sensitizing substance evaluation method
EP2269072B1 (en)*2008-03-312017-08-23Boston Medical Center CorporationPredictive marker for topoisomerase i inhibitors
US20110191868A1 (en)*2008-04-102011-08-04Massachusetts Institute Of TechnologyMethods for identification and use of agents targeting cancer stem cells
KR101692705B1 (en)*2008-12-052017-01-04애브비 인코포레이티드Sulfonamide derivatives as Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010121231A1 (en)2009-04-182010-10-21Genentech, Inc.Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
UA114856C2 (en)*2010-02-112017-08-10Селджин Корпорейшн METHODS OF TREATMENT WITH THE APPLICATION OF ARYLMETOXISOINDOLINE DERIVATIVES
US9128101B2 (en)*2010-03-012015-09-08Caris Life Sciences Switzerland Holdings GmbhBiomarkers for theranostics
CA2808417A1 (en)2010-08-182012-02-23Caris Life Sciences Luxembourg Holdings, S.A.R.L.Circulating biomarkers for disease
CN103492590A (en)2011-02-222014-01-01卡里斯生命科学卢森堡控股有限责任公司Circulating biomarkers
CA2839530A1 (en)*2011-06-162012-12-20Caris Life Sciences Luxembourg Holdings, S.A.R.L.Biomarker compositions and methods
EP3904875B1 (en)2012-06-292024-11-20Celgene CorporationMethods for determining drug efficacy using ikzf3 (aiolos)
US20150038511A1 (en)2012-08-092015-02-05Celgene CorporationTreatment of immune-related and inflammatory diseases
US20140343058A1 (en)2012-08-092014-11-20Celgene CorporationTreatment of systemic lupus erythematosus
UA117141C2 (en)2013-10-082018-06-25Селджин Корпорейшн COMPOSITIONS (S) -3- (4 - ((4- (MORPHOLINOMETHYL) BENZYL) OXY) -1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONE
JP2017522270A (en)2014-05-192017-08-10セルジーン コーポレイション 3- (4-((4- (morpholinomethyl-benzyl) oxy) -1-oxoisoindoline-2-yl) piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Also Published As

Publication numberPublication date
CA2881113C (en)2020-10-27
PL2882441T3 (en)2020-09-21
KR20210073616A (en)2021-06-18
SG11201500983RA (en)2015-04-29
SI2882441T1 (en)2020-08-31
CA3092279A1 (en)2014-02-13
KR20200058606A (en)2020-05-27
US20210340132A1 (en)2021-11-04
LT2882441T (en)2020-07-27
PH12015500276A1 (en)2015-04-27
SMT202000333T1 (en)2020-07-08
CY1123106T1 (en)2021-10-29
HUE049569T2 (en)2020-09-28
KR20150039848A (en)2015-04-13
HRP20200836T1 (en)2020-08-07
NI201500013A (en)2019-05-10
KR102266509B1 (en)2021-06-16
EP2882441A2 (en)2015-06-17
US20140045844A1 (en)2014-02-13
EP3741372A1 (en)2020-11-25
CN115068484A (en)2022-09-20
TWI641371B (en)2018-11-21
AU2013299625B2 (en)2018-02-01
EP2882441B1 (en)2020-04-29
JP6250671B2 (en)2017-12-20
JP6595565B2 (en)2019-10-23
EA029085B1 (en)2018-02-28
WO2014025958A2 (en)2014-02-13
CN108938642A (en)2018-12-07
CA3092279C (en)2023-08-08
ZA201500466B (en)2016-06-29
CN104703605A (en)2015-06-10
HK1211474A1 (en)2016-05-27
NZ727295A (en)2018-06-29
IL237070A0 (en)2015-03-31
WO2014025958A3 (en)2014-04-17
CA2881113A1 (en)2014-02-13
DK2882441T3 (en)2020-05-25
RS60416B1 (en)2020-07-31
UA116992C2 (en)2018-06-11
CN114939119A (en)2022-08-26
MX2015001686A (en)2015-04-10
BR112015002272A2 (en)2017-07-04
JP2018070623A (en)2018-05-10
NZ628077A (en)2017-04-28
PT2882441T (en)2020-06-29
IL237070B (en)2019-06-30
KR102118559B1 (en)2020-06-03
ES2800026T3 (en)2020-12-23
JP2015527349A (en)2015-09-17
TW201408298A (en)2014-03-01
AU2013299625A1 (en)2015-02-12
EA201590342A1 (en)2015-07-30
US10919883B2 (en)2021-02-16

Similar Documents

PublicationPublication DateTitle
PH12015500276A1 (en)Treatment of immune-related and inflammatory diseases
PH12013501837A1 (en)Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
CY1123142T1 (en) IMPROVED METHODS FOR THE PRODUCTION OF POSITIVE CELL THERAPEUTICS
GB201106750D0 (en)Novel compounds
MX2013006040A (en)Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis.
SG195086A1 (en)Compounds containing hydrido-tricyano-borate anions
GB201106743D0 (en)Novel compounds
PH12013500955A1 (en)Spiro-oxindole mdm2 antagonists
MA38860B1 (en) Immune-modulating progenitor cell (imp)
PL3321355T3 (en)Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses
EP2879710A4 (en) AGENTS FOR MODULATING ACTIVATION OF IMMUNE CELLS AND METHODS OF USE THEREOF
NZ630805A (en)Pharmaceutical combinations comprising a thionucleotide analog
MX2015017103A (en)Sc-î² cells and compositions and methods for generating the same.
EP2558124A4 (en)Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2859135A4 (en)Gas permeable electrodes and electrochemical cells
EP2646543A4 (en) METHOD FOR GENERATING CORNEAL CELLS AND CELL POPULATIONS COMPRISING THE SAME
MX359210B (en)Procaspase 3 activation by combination therapy.
IN2015DN02739A (en)
MX2013013649A (en)Quinone compounds for treating ape1 mediated diseases.
EP3202885A4 (en)Novel biological activity testing structure for tracking single cell, using gelling agents
IN2015DN00344A (en)
MX339243B (en)Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof.
IN2014MN01944A (en)
PH12015500420A1 (en)Inhibitors of beta-secretase
PH12015501390A1 (en)Tablets with improved acceptance and good storage stability

Legal Events

DateCodeTitleDescription
FGGrant or registration
[8]ページ先頭
©2009-2025 Movatter.jp